External Validity of a Randomized Trial in Patients With a Femoral Neck Fracture (EXVAL)

August 29, 2016 updated by: Olof Skoldenberg, Danderyd Hospital

External Validity of a Randomized Controlled Trial in Patients With a Femoral Neck Fracture

The aim of this study is to evaluate the external validity of a randomized controlled trial comparing choice of hip arthroplasty for elderly patients (>80 years) with a displaced femoral neck fracture.

The hypotheses are that patient reported hip function, quality of life are better and healthier in those included in the randomized controlled trial than those excluded. The external validity of the randomized controlled trial is acceptable.

A prospective randomized controlled trial is planned and patients with a displaced femoral neck fracture will be included and randomized between either a hemiarthroplasty or total hip arthroplasty. All patients screened will be included in a prospective cohort study for evaluation of the external validity of the randomized controlled trial. The prospective cohort study will consist of 3 different groups.

Patients included in the randomized controlled trial will form group 1. Patients eligible for the randomized controlled trial but did not give their informed consent and therefore excluded, form group 2.

Patients with a femoral neck fracture which by any reason were excluded form group 3.

Primary endpoint is patient-reported hip function (Harris hip score) and pain on the operated extremity evaluated with VAS (Visual Analogue Scale) and patient reported quality of life evaluated with EuroQol (EQ-5D). Secondary outcome measurement are the frequency of the complications, periprosthetic fracture, dislocation, revision surgery due to wound infection (deep and superficial) and loosening of the components. Baseline data, age, sex, comorbidity, cognitive status, weight, height, motor function, complications and reoperations. Follow up is performed 1-2 years after surgery.

Group 1 is followed up in the ongoing randomized controlled trial by visits to the orthopedic department at Danderyd Hospital. Group 2 and 3 are followed up by telephone interview 1-2 year after surgery.

Study Overview

Status

Active, not recruiting

Detailed Description

The aim of this study is to evaluate the external validity of a randomized controlled trial comparing choice of hip arthroplasty for elderly patients (>80 years) with a displaced femoral neck fracture.

The hypotheses are:

  1. The patient reported hip function and quality of life are better in those included in the randomized controlled trial than those excluded.
  2. Patients included in the study are healthier than those excluded.
  3. The external validity of the randomized controlled trial is acceptable, defined as the difference between patients that provide and do not provide their informed consent do not reach clinical significance (a mean difference in Harris hip score of 10 points).

All patients above 80 years old with an acute displaced femoral neck fracture at Danderyds hospital AB during 2009-2016 will be screened and asked for participation in a randomized controlled trial. Those who fulfill the criteria for inclusion and give their informed consent are enrolled in the randomized controlled trial. Patients that will not give their informed consent and those which do not fulfill the inclusion criteria are enrolled in a prospective cohort study for evaluation of the external validity.

The prospective cohort study will consist of 3 different groups. Patients included in the randomized controlled trial study will form group 1. Patients eligible for the randomized controlled trial but did not give their informed consent and therefore excluded, form group 2.

Patients with a femoral neck fracture which by any reason were excluded form group 3.

Follow-up is performed 1-2 years after surgery. Inclusion criteria in the randomized controlled trial.

1. Age above 80 years 2. Acute (<36h) displaced femoral neck fracture. 3. Independent walker 4. Abscence of cognitive impairment (Pfeiffer test >7) 5. Did not fulfill any exclusion criteria Exclusion criteria in the randomized controlled trial

  1. Patient with osteoarthritis or rheumatoid arthritis in the fractured hip
  2. Pathological fracture
  3. Non walker
  4. Cognitive impairment (Short Portable Mental Questionnaire <7)
  5. Contraindication to total hip replacement due to wound, patients with comorbidities, deemed not suitable for a total hip replacement by the anesthesiologist, severe coagulation disorder, and severe drug abuse.
  6. Deemed unsuitable for inclusion by other reason.

    1. Primary endpoint is patient-reported hip function (Harris hip score) and pain on the operated extremity evaluated with VAS (Visual Analogue Scale)
    2. Patient reported quality of life evaluated with EQ-5D.

Secondary outcome:

  1. Secondary outcome measurement are the frequency of the complications, periprosthetic fracture, dislocation, revision surgery due to wound infection (deep and superficial) and loosening of the components.
  2. Baseline data, age, sex, comorbidity, cognitive status, weight, height, motor function and complications and reoperations.

Secondary outcome measurements are obtained in the medical records.

Study Type

Observational

Enrollment (Anticipated)

900

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden, 18288
        • Orthopaedic department, Danderyd Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

80 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

A femoral neck fracture in the elderly patient is a common cause of suffering and premature death in an aging population. Femoral neck fractures are mainly a fragility (osteoporotic) fracture, predominantly affecting women after menopause. Included in the study are elderly patients (>80 years) with a displaced femoral neck fracture.

Description

Inclusion Criteria randomized controlled trials:

  • Age above 80 years
  • Acute (<36h) displaced femoral neck fracture.
  • Independent walker
  • Abscence of cognitive impairment (Short Portable Mental Questionnaire >7points)
  • Did not fulfill any exclusion criteria

Exclusion Criteria randomized controlled trial:

  • Patient with osteoarthritis or rheumatoid arthritis in the fractured hip
  • Pathological fracture
  • Non walker
  • Cognitive impairment (Short Portable Mental Questionnaire <7points)
  • Contraindication to total hip replacement due to wound, patients with comorbidities, deemed not suitable for a total hip replacement by the anesthesiologist, severe coagulation disorder, and severe drug abuse.
  • Deemed unsuitable for inclusion by other reason.

Inclusion into prospective cohort study

  • Included into the randomized controlled trial.
  • Did not give their informed consent for participation in the randomized controlled trial.
  • Patients above 80 years of age excluded from participation in the randomized controlled trial due to fulfillment of exclusion criteria or did not fulfill inclusion criteria.

Exclusion into prospective cohort study

  • Age below 80 years of age.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Included
Patients included into the randomized controlled trial
Non-consenters
Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
Excluded
Patients, by different reasons excluded from participation in the randomized controlled trial.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Harris hip score
Time Frame: Up to 2 years
Hip function as a patient reported outcome measurement
Up to 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline data (Preoperative baseline data obtained at admission to the hospital)
Time Frame: 1 day
Age, sex, date of surgery, type of surgical treatment, surgical approach, time, level of competence of the treating surgeon, American Society of Anesthesiologists grade determined by treating anesthesiologist, surgical time, patients weight and length
1 day
Mortality
Time Frame: up to 2 years
up to 2 years
Complications (Any reason to reoperation)
Time Frame: up to 4 years years
Any reason to reoperation most commonly prosthetic dislocation, deep infection, periprosthetic dislocation
up to 4 years years
EQ-5D
Time Frame: up to 2 years
Health related quality of life, patient reported outcome
up to 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Olof G Skoldenberg, MD, PhD, Department of clinical sciences at Danderyds hospital, Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2009

Primary Completion (Anticipated)

October 1, 2018

Study Completion (Anticipated)

October 1, 2027

Study Registration Dates

First Submitted

January 26, 2015

First Submitted That Met QC Criteria

February 12, 2015

First Posted (Estimate)

February 13, 2015

Study Record Updates

Last Update Posted (Estimate)

August 30, 2016

Last Update Submitted That Met QC Criteria

August 29, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • External validity

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hip Fracture

Subscribe